Latest 20-F annual reports

Nano-X Imaging Ltd. reports its fiscal year 2024 results, showcasing FDA clearances for its Nanox.ARC system and strategic moves towards global commercialization.

Kelso Technologies Inc. announces its fiscal year 2024 results, navigating a challenging economic landscape with a net loss of $4.62 million despite consistent revenue.

Vista Energy Argentina secures a 10-year extension for its hydrocarbon exploitation and transportation concessions in the province of Ro Negro, Argentina, ensuring continued operations and investments.

Brazil Potash Corp. files an amendment to its 20-F annual report to include Exhibit 101, containing interactive data files in Inline XBRL.

NIO Inc. has filed its 20-F report with the SEC, detailing its financial performance and operational activities for the fiscal year ended December 31, 2024.

Simpple Ltd.'s FY2024 results reveal a revenue decrease, attributed to contract delays, alongside ongoing investments in R&D and international expansion.

Millicom International Cellular S.A. announces a transformative 2024 marked by significant operating profit growth, debt reduction, and strategic initiatives to strengthen its core business in Latin America.

Eltek Ltd. reports its 20-F filing for the fiscal year ended December 31, 2024, highlighting a slight revenue decrease and addressing risks related to geopolitical instability and operational challenges.

YY Group Holding Limited's 2024 annual report reveals a 29.4% increase in revenue, but a significant net loss due to increased operating and administrative expenses.

PainReform Ltd. files its 20-F, detailing 2024 financials and outlining a strategic move into AI-driven solar analytics with the acquisition of DeepSolar.

NeuroSense Therapeutics reports its 2024 financial results, highlighting its focus on developing treatments for neurodegenerative diseases and providing an update on its clinical programs.

Frontline plc's 20-F filing summarizes the company's financial performance, fleet composition, and compliance with regulatory requirements for the fiscal year ended December 31, 2024.

Logistic Properties of the Americas files an amendment to its annual report on Form 20-F to correct an inadvertently marked checkbox regarding filing requirements.

HomesToLife Ltd reports a significant net loss for 2024, driven by declining revenue, increased expenses, and one-time listing costs, despite efforts to expand into new markets and optimize operations.

Pharvaris N.V. files its annual report, detailing its financial status and progress in developing innovative therapies for rare diseases, particularly angioedema.

Golden Heaven Group Holdings Ltd. files an amendment to its annual report on Form 20-F to address SEC comments, acknowledging material weaknesses in internal control over financial reporting.

Titan America SA's 20-F filing provides a detailed overview of the company's financial performance, strategies, and risk factors for the fiscal year ended December 31, 2024.

Chemomab Therapeutics announces positive clinical data from its PSC SPRING study and alignment with the FDA on a Phase 3 registration study for nebokitug, a potential treatment for Primary Sclerosing Cholangitis.

BBVA Argentina's 20-F filing highlights the bank's performance amidst Argentina's economic volatility, regulatory shifts, and strategic efforts to diversify its lending portfolio.

Chanson International Holding announces its fiscal year 2024 results, showcasing revenue growth but also highlighting challenges related to competition and internal control weaknesses.

Eni SpA's 20-F filing provides a comprehensive overview of the company's financial results, strategic initiatives, and risk factors for the fiscal year ended December 31, 2024.

Petrobras filed its 2024 annual report detailing a sharp 69.7% decrease in net income while reaffirming its commitment to balancing oil and gas production with investments in energy transition and low-carbon initiatives.

MKDWELL Tech Inc.'s annual report reveals a year of strategic adjustments amid economic headwinds, impacting revenue and profitability.

Apollomics Inc.'s 20-F filing reveals ongoing net losses and a need for additional capital, despite advancements in its oncology pipeline and a recent licensing agreement.

J-Long Group Limited files an amendment to its 20-F annual report, providing updated financial information and disclosures.

BGM Group Ltd files an amendment to its 20-F form for the fiscal year ended September 30, 2024, detailing its financial results and corporate structure.

I-Mab reports its 2024 financial results and details a strategic realignment focusing on its lead program, givastomig, while reducing workforce by 27%.

Super Group (SGHC) Limited announces its financial results for the year ended December 31, 2024, showcasing revenue growth and strategic shifts.

Aurora Mobile Limited files its 20-F, highlighting financial results for fiscal year 2024 and addressing ongoing regulatory challenges in the PRC.

Pharming Group N.V. reports increased revenue driven by RUCONEST sales and highlights strategic pipeline expansion with Joenja and the acquisition of Abliva AB in its 20-F filing.